Immunology

Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets…

- Multi-year, multi-program R&D partnership to deliver innovative treatment options across cancer and immunological diseases

- Frontier eligible to receive up to $100 million in upfront and milestone payments within the first 12 months of collaboration

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Dec. 2, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Frontier Medicines, Corp., a precision medicine company drugging challenging protein targets to develop breakthrough medicines that change the course of human diseases, today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative small molecule therapeutics against high-interest, difficult-to-drug protein targets.

Under the multi-year collaboration, AbbVie and Frontier will utilize Frontier's proprietary chemoproteomics platform to identify small molecules for programs directed to novel E3 ligases and certain oncology and immunology targets. Whereas conventional drug discovery methodologies have been primarily successful against a relatively discrete set of target classes, chemoproteomics-based screening in relevant cellular contexts has the potential to enable targeting of a significantly broader range of proteins. By selecting certain immunology and oncology targets for the collaboration that are considered well validated but to date, inaccessible, the collaboration has the potential to develop highly differentiated and efficacious therapeutics.

Under the terms of the agreement, AbbVie will pay Frontier an upfront cash payment of $55 million, and Frontier is eligible to receive additional milestone payments. In addition, AbbVie will reimburse Frontier's R&D costs through defined stages of pre-clinical development. The companies will collaborate on the research and pre-clinical development of programs directed against E3 ligase, immunology and oncology targets. Upon successful completion of defined stages of pre-clinical development, AbbVie will assume full responsibility for global development and commercialization activities and costs for the programs. Frontier will retain an option to share development activities and expenses for certain oncology programs through the completion of Phase 2. Frontier will be eligible to receive success-based development and commercial milestone payments that could potentially exceed $1 billion, in addition to royalty payments on commercialized products. AbbVie retains the right to expand the collaboration in the future by exercising options to a defined number of additional targets. The collaboration excludes all of Frontier's internal programs for which Frontier retains exclusive global rights.

Story continues

"AbbVie is focused on making investments in promising new technologies that assist us in our mission to develop innovative medicines," said Jose-Carlos Gutirrez-Ramos, Ph.D., vice president, Discovery, AbbVie. "One of our key strategic focus areas is targeted protein degradation and chemoproteomics, and this collaboration with Frontier Medicines will be highly synergistic and complementary to our ongoing efforts."

"AbbVie's commitment to innovative therapies makes them an ideal partner in the development and commercialization of new medicines for cancer and immunological diseases," said Chris Varma, Ph.D., Frontier's co-founder, chairman, and CEO. "With our powerful chemoproteomics platform, we are greatly expanding the universe of therapeutic targets that can be accessed with small molecule drugs. This partnership enables us to build a shared pipeline of novel therapeutics with AbbVie, while Frontier continues to independently advance our internal programs into the clinic."

About Frontier MedicinesFrontier Medicines is a precision medicine company that has pioneered a proprietary discovery and development platform to develop medicines against disease-causing proteins previously considered undruggable. The company is deploying its groundbreaking scientific approaches in chemoproteomics, covalent drug discovery, and machine learning to develop medicines to treat a number of debilitating diseases, starting with cancer. In its quest to "drug the undruggable," Frontier Medicines seeks to significantly broaden the therapeutic landscape with novel small molecule alternatives to change the course of a broad range of diseases. For more information, visit http://www.frontiermeds.com and follow us on LinkedIn.

About AbbVieAbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at http://www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube, and LinkedIn.

Forward-Looking StatementsSome statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2019 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Frontier Medicines Media:pr@frontiermeds.com

AbbVie Media:Gentry Lassiter(224) 219-6670gentry.lassiter@abbvie.com

AbbVie Investors:Liz Shea(847) 935-2211liz.shea@abbvie.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/frontier-medicines-and-abbvie-establish-global-partnership-to-discover-and-develop-novel-therapies-and-e3-degraders-against-difficult-to-drug-targets-301183478.html

SOURCE Frontier Medicines

View original post here:
Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets...

Immunology

Expanding early peanut introduction can increase prevention efforts – Contemporary Pediatrics

Earlypeanut introduction has been recommended to pre-emptively address peanut allergies in at-risk children with positive skin prick tests for some time now, but a new study reveals the potential of peanutintroductionas a preventive tool in other groups, as well.

The Learning Early About Peanut Allergy (LEAP) trial and other studies have shown the benefit ofearly peanut introductionin helping children aged younger than 5 years who are at-risk of developing a peanut allergy. However, these studies have excluded infants whose skin prick tests were greater than 4 mm. Additionally, current guidelines forearly peanut introductionrecommend oral food challenges only in infants who have skin prick tests 7 mm. There is no guidance for infants whose skin prick tests are >7 mm or who have high peanut immunoglobulin E (IgE) levels. Adding to the difficulty in addressing oral food challenges in these populations is the lack of standardized values for skin prick testing and IgE levels in infants with peanut allergies.

A new study, published in theAnnals of Allergy, Asthma, and Immunology, sought to test oral food challenges in a wider group than had previously been allowed under current guidelines.1 Specifically, the research team investigated whethersmaller, 1-gram doses ofpeanutwould be tolerated inchildren who typically are not offered oral food challenges.

We've seen that strict avoidance at a young age does not prevent peanut allergy and may promote it in some at-risk children, says lead author Adora A. Lin, MD, PhD, FAAAAI, principal investigator for the Center for Cancer and Immunology Research at the Childrens National Research Institute and attending physician at Childrens National Hospital in Washington, DC. The exact mechanisms are unknown, but the general idea is that allergen exposure through the gut can lead to a tolerizing immune response, whereas allergen exposure through the skinespecially eczema-inflamed skincan lead to an allergic immune response. We see low dose peanut introduction as a strategy to allow more children get peanut in the diet at a young age to hopefully prevent peanut allergy.

From an allergist's perspective, many allergists are fearful to offer peanut food challenges to infants with larger peanut skin prick tests, and require them to consume doses larger than 1 gram to "prove" that they are not allergic, Lin reveals.

We see peanut food challenges with a lower dose as an opportunity to facilitate peanut introduction in some at-risk patients, she says.

Lin referenced a 2019 survey that showed several barriers to peanut introduction in infants, including fear of reactions, choking, and a lack of infant-safe forms of peanut.

In the same survey, only 60% of physicians provided recommendations consistent with National Institute of Allergy and Infectious Disease (NIAID) guidelines, with physician-perceived barriers of parental acceptance of guidelines and fear of giving peanut, and identified educational handouts and access to infant-safe forms of peanut as needed resources, Lin says. The data suggest that both families and physicians would benefit from further education on practical aspects of peanut introduction.

The research team tested the tolerance of a one-gram peanut challenge in infants regardless of skin prick testsizeorpeanutIgE results over a 2-year period in the retrospective study. Of the infants with a skin prick test equal to or smaller than 4 mm, 97% were tolerant of low-dose challenges. In children with skin prick tests larger than 4 mm, 63% were low-dose tolerant. Additionally, the researchers found that Ara h2 IgE levels were significantly lower in the children who did well with the tests compared to those who were not tolerantto the oral challenge. This suggests that Ara h2 IgE levels might be predictive to tolerance of oral food challenges in some infants, the study notes. In this regard, the study concludes that low dose peanut oral food challenges with a gradual increase in dosing may help prevent peanut allergies in a larger number of children at risk of developing these allergies.

Current NIAID guidelines for early peanut introduction recommend peanut introduction orsupervisedoral food challenge for infants with peanut skin prick tests 7 mm in size and do not specifically address management of infants with peanut skin prick tests 7 mm, Lin says. Based on previous studies, these infants are typically advised to avoid peanut. However, in our study, we showed that over 50% of these infants can tolerate a low dose of peanut and can increase the dose at home.

This means that supervised introduction of a low dose of peanut can be done safely for a wider population of infants than previously thoughtpotentially benefiting a larger population of infantsand that families can gradually increase the dose of peanut their infants eat at home, Lin says.

Multiple studies have provided evidence that early introduction of peanut can decrease the incidence of peanut allergy, leading to guidelines from NIAID, the American Academy of Pediatrics, and clinical organizations around the world to recommend early introduction of peanut. However, due to certain risk factors and test results, many physicians may be hesitant to offer introduction of peanut to certain infants, Lin notes. In addition, infants developing feeding skills and preferences may have difficulties eating larger quantities of solid food. We encourage allergists to consider offering supervised introduction of peanut to infants with large peanut skin prick tests, and present the low1 gramdose and home increase in the dose as a strategy that will allow incorporation of peanut into the diet in a developmentally accommodating manner.

New guidelines from the American Academy of Allergy, Asthma, and Immunology and the American College of Allergy, Asthma, and Immunology are on the way, Lin reveals, adding that she hopes the report will encourage allergists to offer oral food challenges to infants with large skin prick tests who would otherwise be advised to avoid oral food challenges.

Although risks still exist, our approach allows a wider population of infants to undergo dietary introduction of peanut in a supervised setting, with continued dietary incorporation at home and potentially decreasing the risk of developing peanut allergy in more infants, Lin says.

Reference

1. Lin A, Uyguygil B, Robbins K, Ackerman O, Sharma H. Low-dose peanut challenges can facilitate infant peanut introduction regardless of skin prick test size. Annals of Allergy, Asthma & Immunology. 2020;125(1):97-99. doi:10.1016/j.anai.2020.03.026

See more here:
Expanding early peanut introduction can increase prevention efforts - Contemporary Pediatrics

Immunology

Enthera Pharmaceuticals Appoints Kazumi Shiosaki to Its Board of Directors and Lisa Olson to Its Scientific Advisory Board to Push Forward Company…

Enthera Pharmaceuticals ("Enthera"), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, announces that it has appointed Kazumi Shiosaki to its Board of Directors, and Lisa Olson to its Scientific Advisory Board.

Kazumi brings experience as both an entrepreneur and an investor within the field of biotechnology. She is currently the CEO of Twentyeight-Seven, a biotech company focused on novel RNA biology that she co-founded alongside prominent Harvard investigators. Kazumi was also a co-founder and CEO of Mitobridge, a start-up company developing mitochondrial drugs for the treatment of muscle and kidney diseases, until its acquisition by Astellas Pharma in 2018. Prior to Mitobridge, she was a co-founder and start-up CEO of Epizyme (NASDAQ:EPZM), a leader in novel epigenetic therapeutics for cancer. She has also been a Managing Director at MPM Capital.

Lisa is a senior pharmaceutical executive with more than 20 years of experience in research and drug discovery. She is currently Chief Scientific Officer and Head of Research at Magenta Therapeutics, where she provides strategic direction, oversight and execution for research and discovery efforts. Lisa joined Magenta after 15 years in leadership positions at the AbbVie Bioresearch Center, most recently as Vice President, Immunology Discovery and Site Head, where she was responsible for all immunology discovery scientific and portfolio decisions. Prior to AbbVie, Lisa served as a Research Fellow and Group Leader in Inflammation & Immunology at Pfizer.

Kazumi and Lisa will work closely with the leadership team and other Board and Scientific Advisors to support the growth and development of Enthera.

Giovanni Amabile, CEO of Enthera, commented: "The appointment of Kazumi Shiosaki and Lisa Olson will greatly benefit Enthera. Kazumi is a biotech veteran with an outstanding track record in corporate development and fundraising across both European and US markets, while Lisa brings extensive experience in drug discovery and development from roles at Magenta Therapeutics, AbbVie and Pfizer. The support of Kazumi and Lisa will be instrumental as we progress our pipeline and take Enthera to the next level."

Story continues

Kazumi Shioshaki, newly appointed Board member of Enthera, stated: "Enthera Pharmaceuticals is an exciting young biotech, with an innovative and unique approach to treating underserved autoimmune disorders. The recent Series A financing round was a great achievement, and I look forward to working with the Enthera team as we push onwards and use these funds to build a world-class international company with first-in-class therapeutics."

Lisa Olson, newly appointed Scientific Advisory Board member, added: "I look forward to supporting Giovanni and the rest of the Enthera team in the progression of their clinical assets. The Companys lead product is a promising biologic candidate for type 1 diabetes and gastrointestinal diseases, with the wider pipeline offering potential treatments for several underserved autoimmune conditions."

Enthera recently closed a EUR 28 million funding, with investment from renowned investors Sofinnova Partners, AbbVie and JDRF T1D Fund. The funds will be used to accelerate the Companys lead program, Ent001, to clinical proof-of-concept.

Kazumi started her career at AbbVie (then Abbott Labs) and from there joined Millennium (now part of Takeda), where she worked in senior functions in both research and corporate development. She is also a Board member of the Sandford Burnham Prebys Institute. Kazumi holds a PhD in Synthetic Chemistry from UC Berkeley.

Lisa began her career as Assistant Professor at Washington University School of Medicine, following a post-doctoral cardiovascular fellowship at the University of Chicago. She holds a PhD from the University of Illinois at Urbana-Champaign, and a Bachelor of Science from Iowa State University.

ENDS

High-resolution photos of Kazumi Shiosaki and Lisa Olson are available upon request.

Notes to Editors

About Enthera

Enthera Srl is a biotech company developing first-in-class biologics to transform the treatment paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way. The Companys primary target indications are type 1 diabetes (T1D) and inflammatory bowel disease (IBD).

Enthera's pioneering approach capitalizes on the key discovery of the IGFBP3/TMEM219 pathway, which is involved in beta cell and stem cell apoptosis in pancreas and gut, respectively.

The Company is building a pipeline of inhibitory monoclonal antibodies (mAbs) and fusion proteins targeting the pathway via multiple angles. Its lead program Ent001 is the only drug in development with the potential to restore the endogenous pancreatic stem cell compartment in T1D as well as the original intestine structure in IBD, in order to re-stablish organ function.

Enthera is a private company headquartered in Milan, Italy and founded in 2016 by Prof Paolo Fiorina and Dr Francesca DAddio at BiovelocITA, an Italian biotech accelerator. The Company is backed by Sofinnova Partners and JDRF T1D fund. Entheras discovery engine and assets are protected by a broad portfolio of patents.

For more information, visit https://www.entherapharmaceuticals.com/

Connect with us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201203005055/en/

Contacts

Enthera Pharmaceuticals Giovanni Amabile, CEOE: info@entherapharmaceuticals.com

Instinctif Partners (media enquiries) Dr Christelle Kerouedan / Siobhan Sanford / Kiki ZaccagniniTel: +44 20 7457 2020E: enthera@instinctif.com

More:
Enthera Pharmaceuticals Appoints Kazumi Shiosaki to Its Board of Directors and Lisa Olson to Its Scientific Advisory Board to Push Forward Company...

Immunology

Allergy experts weigh in on prevention strategies – Contemporary Pediatrics

The American Academy of Allergy, Asthma, and Immunology (AAAAI) has unveiled new guidelines on preventing allergies and asthma in children.1 The guidance, updated in September, reviews a number of strategies to prevent, or even delay, the development of several types of allergies.

Food Allergies

Food allergies are a big deal in children, who arent always able to be choosy when it comes to what they eat. Children can have a difficult time discerning the content of some foods, and parents cant always be with them. This makes prevention key when it comes to food allergies, which can be triggered by a number of foods like peanuts, cows milk, eggs, and more.

Infants who have a sibling or at least 1 parent with an allergic condition are particularly at risk of developing food allergies, especially if they already show symptoms of foods allergies like atopic dermatitis, allergic rhinitis, or asthma.

There are a number of methods that helpand others that dontthat were reviewed in the guidance.

Environmental Allergies

There are a number of environmental factors that can trigger allergies, too. However, unlike foods, early contact with environmental allergens can make allergies worse. Research is the most robust when it comes to dust mites, according to AAAAI, which suggests working to control dust mites early to prevent allergy problems. Some solutions to control environmental allergens recommended in the guidance include:

Pet are different, though, according to AAAAI, with recent research suggesting that early exposure to pets can actually help protect children from developing allergies.

When You Need Help

The AAAAI also offered guidance on when to get help and where. If possible, the organization recommends finding an allergist specifically, as they have received specialized training in allergy and immunology. Allergy testing by a specialist can give detailed information about an allergy, and the best methods for treatment, according to AAAAI. On the other hand, AAAAI recommends against massive allergy screening tests done in retail sites, applied kinesiology, or testing through muscle relaxation, cytotoxicity testing, skit titration, provocative and neutralization testing, or sublingual provocation.

Kari Christine Nadeau, MD, PhD, Naddisy Foundation Endowed Professor of Medicine and Pediatrics and director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University in Palo Alto, California says its important that advice be given on science and epidemiological studies. In terms of allergy prevention, research studies show that a diversification of diets with a variety of proteins from different food sources introduced all at oncerather than staged as suggested by AAAAIcan decrease the risk of allergy and asthma development.

There are a number of other tips she offers for allergy prevention, including:

Nadeau also makes it clear that vaccination avoidance is not a prevention strategy for allergens, and that allergy prevention can begin at any age.

Reference

1. American Academy of Allergy, Asthma & Immunology. Prevention of allergies and asthma in children. Reviewed September 28, 2020. Accessed December 2, 2020. https://www.aaaai.org/conditions-and-treatments/library/allergy-library/prevention-of-allergies-and-asthma-in-children.

Visit link:
Allergy experts weigh in on prevention strategies - Contemporary Pediatrics

Immunology

Contract Research Organizations (CROs) Market to Reach $64.4 Billion by 2027, Growing at a CAGR of 6 – PharmiWeb.com

LONDON, Dec. 4, 2020 /PRNewswire/ -- A contract research organization (CRO), also known as a clinical research organization, is a service provider organization, which supports pharmaceutical and biotechnology companies for drug development and medical device companies by providing outsourcing services.In recent years, pharmaceutical companies have increased their investment in outsourcing clinical activities, which further supported the growth of the contract research organizations market.

DownloadFree Sample Report Now @https://www.meticulousresearch.com/download-sample-report/cp_id=5129

Meticulous Research,in its latest publication, titled "Contract Research Organizations (CRO) Marketby Services (Clinical Research [Phase II, Phase III], Pre-Clinical [Pharmacokinetics, Toxicology], Laboratory Services, and others), Therapeutic Area (Oncology, Immunology), End User (Pharma and Biotech, Medical Device), and Geography - Forecast to 2027",states that the contract research organizations (CROs) market is poised to grow at a CAGR of 6.5% from 2020 to 2027 to reach $64.4 billion by 2027.

The growth of the contract research organizations market is mainly attributed to the rising demand for biopharmaceuticals, increasing number of clinical trials, and growing government support for biopharmaceutical manufacturing. Also, significant opportunities from emerging markets, increasing demand for biosimilars, and continuous advancements in bioprocessing techniques offer growth opportunities for the players operating in the contract research organizations market.

To provide efficient analysis, Meticulous Research has segmented the overall CROs market based on service (clinical research [phase II and phase III], pre-clinical [pharmacokinetics and toxicology], laboratory services, and others), therapeutic area (oncology and immunology), end user (pharma & biotech and medical device), and geography (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa).

Speak to our Analysts to Understand the Impact of COVID-19 on Your Business:https://www.meticulousresearch.com/speak-to-analyst/cp_id=5129

Geographically, in 2020, North America is estimated to command the largest share of the global contract research organizations market, followed by Asia-Pacific. The major share of this region is mainly attributed to the growing investments in the pharmaceutical and biopharmaceutical industries, greater adoption of advanced technologies, rising prevalence of non-communicable diseases, growth in drug development programs, and the presence of key service providers. Further, the growth during the forecast period will be driven by the expected rise in the demand for biosimilars - due to the patent expiry of many innovators' molecules in the next 5 to 10 years.

In terms of service, the clinical research services segment is estimated to account for the largest share of the overall CROs market in 2020. The large share of this segment is mainly attributed to an increase in the number of clinical trials globally, growth in outsourcing activities to conduct clinical trials at low costs, and growth in collaborations between key players and clinical service providers to reduce failures.

Based on therapeutic area, the oncology segment is estimated to account for the largest share of the overall contract research organizations market in 2020. The large share of this segment is mainly attributed to an increase in the number of oncology clinical trials globally, growth in government investments for the development of personalized medicines for oncology, and high demand for biosimilars for cancer.

Quick Buy CROs Market Research Report:https://www.meticulousresearch.com/buy_now.php?pformat=433&vformat=1285

By end user, the pharmaceutical and biotechnology companies segment is estimated to account for the largest share of the overall CROs market in 2020. The major share of this segment is primarily attributed to an increase in R&D investments for drug development, growing collaborations of pharmaceutical companies with CROs to conduct clinical trials, and government initiatives to support the growth of pharmaceutical companies.

The report includes a competitive landscape based on extensive assessment of the key strategic developments by leading market participants in the industry over the past four years. The key players profiled in the global contract research organizations market report are IQVIA Holdings Inc. (U.S.), Laboratory Corporation of America Holdings (U.S.), Charles River Laboratories International, Inc. (U.S.), Wuxi Apptec Co., Ltd. (China), Medpace Holdings, Inc. (U.S.), PRA Health Sciences, Inc. (U.S.), Syneos Health, Inc. (U.S.), PARAXEL International Corporation (U.S.), Envigo RMS LLC (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), and SGS S.A. (Switzerland).

To gain more insights into the market with a detailed table of content and figures, click here:https://www.meticulousresearch.com/product/CRO-market-5129/

Scope of the Report:

Contract Research OrganizationsMarket, by Service

Contract Research Organizations Market, by Therapeutic Area

Contract Research Organizations Market, by End User

Contract Research OrganizationsMarket, by Geography

DownloadFree Sample Report Now @https://www.meticulousresearch.com/download-sample-report/cp_id=5129

Amidst this crisis, Meticulous Researchis continuously assessing the impact of COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. Let us know if you would like to assess the impact of COVID-19 on any industry here-https://www.meticulousresearch.com/custom-research.php

Related Reports-

Research Antibodies and Reagents Market by Product {Antibodies [Type (Primary, Secondary), Production, Source, Research Area (Oncology, Neurology)], Reagents}, Technology (ELISA, Western Blot), Application, End User (Pharma, Academia) - Global Forecast to 2027

https://www.meticulousresearch.com/product/research-antibodies-reagents-market-5055/

Medical Device Testing Market by Service Type (Testing and Certification) Location, Technology (Active Implant, Active Medical, In-Vitro Diagnostic, Ophthalmic, Orthopedic and Dental, Vascular), Device Class, and Geography Global Forecast to 2027

https://www.meticulousresearch.com/product/medical-device-testing-market-5131/

Plasma Fractionation Market by Product [Immunoglobulins (Intravenous, Subcutaneous), Coagulation Factors, Albumin], Application (Immunology, Hematology, Neurology), and End User (Hospital, Clinical Research Lab, Academic Institutes) - Forecast to 2027

https://www.meticulousresearch.com/product/plasma-fractionation-market-5117/

About Meticulous Research

Meticulous Research was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.

Contact:

Mr. Khushal Bombe Meticulous Research Direct Lines: +1-646-781-8004 (North America) +44-203-868-8738 (Europe) +91 744-7780008 (Asia-Pacific) Email- sales@meticulousresearch.com Visit Our Website: https://www.meticulousresearch.com/ Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research Content Source: https://www.meticulousresearch.com/press-release/cro-market-2027/490

Logo: https://mma.prnewswire.com/media/1213534/Meticulous_Research_Logo.jpg

See original here:
Contract Research Organizations (CROs) Market to Reach $64.4 Billion by 2027, Growing at a CAGR of 6 - PharmiWeb.com

Immunology

PureTech to Host Virtual R&D Day for Investors on December 11, 2020 – Business Wire

BOSTON--(BUSINESS WIRE)--PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (PureTech or the Company), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, will host its first R&D Day on Friday, December 11, 2020, beginning at 9:00 a.m., Eastern Time. The virtual program will showcase PureTechs scientific leadership in lymphatics and related immune pathways and share insights across its Wholly Owned Pipeline, which includes LYT-100, a clinical-stage anti-fibrotic and anti-inflammatory product candidate being advanced for the potential treatment of interstitial lung diseases and lymphedema, and LYT-200, a product candidate targeting foundational immunomodulatory mechanisms for the potential treatment of solid tumors.

In addition to presentations by PureTechs senior team, the R&D Day will feature talks from renowned scientists and physicians, including:

PureTechs inaugural R&D Day is an opportunity to bring together field-leading experts within our expansive global network to discuss the unique therapeutic opportunities within lymphatics and related immunology, said Daphne Zohar, chief executive officer of PureTech Health. We have made great progress across our Wholly Owned Pipeline, which now includes four product candidates and three discovery platforms, and we look forward to detailing our differentiated approach towards addressing major diseases.

The agenda for PureTechs R&D Day is:

Opening Remarks

Lymphatic Science Overview

Fibrotic and Inflammatory Conditions Unmet Need and LYT-100

Immuno-Oncology Prioritizing Targets and Future Directions

Closing Remarks

A webcast of the event will be available on the Investors section of PureTechs website under Events & Presentations.

To register for PureTechs R&D Day, please sign up here.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTechs Founded Entities, is comprised of 24 products and product candidates, including two that have received U.S. Food and Drug Administration (FDA) clearance and European marketing authorization. All of the underlying programs and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Companys unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

For more information, visit http://www.puretechhealth.com or connect with us on Twitter @puretechh.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking statements, including statements that relate to our product candidates and approach towards addressing major diseases, future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, our expectations regarding the potential therapeutic benefits of PureTechs product candidates and those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Original post:
PureTech to Host Virtual R&D Day for Investors on December 11, 2020 - Business Wire

Immunology

Ireland ‘likely’ to return to lockdown in New Year according to immunology expert – Irish Post

A RETURN to lockdown is likely to happen again in Ireland before Covid-19 vaccinations can be effectively administered around the country.

The Covid-19 vaccine task-force is set to meet this afternoon, as Ireland enters the final day of Level Five restrictions.

They will be deciding how the approved vaccines will be rolled out nationwide once they become available.

But despite the impending vaccines, an Irish immunology expert says he believes that further restrictions, akin to Level Five, may be needed again.

Professor Paul Moynagh insists that more targeted restrictions will be necessary to prevent further waves of the virus, at least until the vaccine has been widely administered.

He expressed concern that if Covid-19 case numbers rose steeply enough once Level Five restrictions were eased, a third lockdown would be needed.

Prof Moynagh described this as a "flawed" method of controlling the virus.

Minister for Health Stephen Donnelly says that he expects the vaccines to be rolled out in early January next year, but immunology professor at Trinity College Luke O'Neill reckons they could be administered sooner.

"It's just a logical question once it's given the green light which is what we are waiting for," Prof O'Neill said.

"In America, they are saying their vaccination programme will begin on December 11, and it shouldn't be any different in Europe really."

The Government said on Monday that it expects Covid-19 cases around the country to rise as lockdown lifted and people mix houses over Christmas, but refused to confirm the likelihood of a third lockdown in the New Year.

Go here to read the rest:
Ireland 'likely' to return to lockdown in New Year according to immunology expert - Irish Post

Physiology

The role of the microbiota in human genetic adaptation – Science

Getting to the guts of local evolution

The microbiota of mammals is a product of coevolution. However, humans exhibit a range of adaptive peculiarities that can be quite geographically specific. The human microbiota also displays a variety of community compositions and a range of overlapping and redundant metabolic characteristics that can alter host physiology. For example, lactase persistence is a genetic characteristic of European populations, but in populations lacking the lactase gene, milk sugar digestion is endowed by the microbiota instead. Suzuki and Ley review the evidence for the role that the microbiota plays in local adaptation to new and changing human circumstances.

Science, this issue p. eaaz6827

When human populations expanded across the globe, they adapted genetically to local environments in response to novel selection pressures. Drivers of selection include exposure to new diets, climates, or pathogens. Humans harbor microbiotas that also respond to changes in local conditions and changes in their hosts. As a result, microbiotas may alter the adaptive landscape of the host through modification of the environment. Examples include changes to a foods nutritional value, the hosts tolerance to cold or low amounts of oxygen, or susceptibility to invading pathogens. By buffering or altering drivers of selection, the microbiota may change host phenotypes without coevolution between host and microbiota. Functions of the microbiota that are beneficial to the host may arise randomly or be acquired from the environment. These beneficial functions can be selected without the host exerting genetic control over them. Hosts may evolve the means to maintain beneficial microbes or to pass them to offspring, which will affect the heritability and transmission modes of these microbes. Examples in humans include the digestion of lactose via lactase activity (encoded by the LCT gene region) in adults and the digestion of starch by salivary amylase (encoded by the AMY1 gene)both are adaptations resulting from shifts in diet. The allelic variation of these genes also predicts compositional and functional variation of the gut microbiota. Such feedback between host alleles and microbiota function has the potential to influence variation in the same adaptive trait in the host. How the microbiota modifies host genetic adaptation remains to be fully explored.

In this paper, we review examples of human adaptations to new environments that indicate an interplay between host genes and the microbiota, and we examine in detail the LCTBifidobacterium and the AMY1Ruminococcus interactions. In these examples, the adaptive host allele and adaptive microbial functions are linked. We propose host mechanisms that can replace or recruit beneficial microbiota functions during local adaptation. Finally, we search for additional examples where microbiotas are implicated in human genetic adaptations, in which the genetic basis of adaptation is well described. These range from dietary adaptations, where host and microbial enzymes can metabolize the same dietary components (e.g., fatty acid and alcohol metabolism), through climate-related adaptations, where host and microbes can induce the same physiological pathway (e.g., cold-induced thermogenesis, skin pigmentation, and blood pressure regulation), to adaptations where hosts and microbes defend against the same local pathogens (e.g., resistance to malaria, cholera, and others). These examples suggest that microbiota has the potential to affect host evolution by modifying the adaptive landscape without requiring coevolution.

Well-studied examples of local adaptation across diverse host species can be revisited to elucidate previously unappreciated roles for the microbiota in host-adaptive evolution. In the context of human adaptation, knowledge of microbial functions and host genemicrobe associations is heavily biased toward observations made in Western populations, as these have been the most intensively studied to date. Testing many of the interactions proposed in this Review between host genes under selection and the microbiota will require a wider geographic scope of populations in their local contexts. Because genes under strong selection in humans are often involved in metabolic and other disorders and can vary between populations, future investigations of host genemicrobe interactions that relate to human adaptation may contribute to a deeper understanding of microbiota-related diseases in specific populations. Investigating host genemicrobe interactions in a wider variety of human populations will also help researchers go beyond collections of anecdotes to form the basis of a theory that takes microbial contributions to host adaptation into account in a formal framework. A better understanding of reciprocal interactions between the host genome and microbiota in the context of adaptive evolution will add another dimension to our understanding of human evolution as we moved with our microbes through time and space.

When human populations adapt genetically to new environments, their microbiotas may also participate in the process. Microbes can evolve faster than their host, which allows them to respond quickly to environmental change. They also filter the hosts environment, thereby altering selective pressures on the host. Illustrated here are examples of interactions between adaptive host alleles and adaptive microbiota functions where the microbiota likely modified the adaptive landscape in response to changes in diet (e.g., changes in levels of starch and milk consumption), exposure to local pathogens (e.g., malaria parasites and Plasmodium spp.), and changes in local climate (e.g., cold stress and hypoxia). In this paper, we discuss the resulting relationships between host-adaptive alleles and microbiota functions.

As human populations spread across the world, they adapted genetically to local conditions. So too did the resident microorganism communities that everyone carries with them. However, the collective influence of the diverse and dynamic community of resident microbes on host evolution is poorly understood. The taxonomic composition of the microbiota varies among individuals and displays a range of sometimes redundant functions that modify the physicochemical environment of the host and may alter selection pressures. Here we review known human traits and genes for which the microbiota may have contributed or responded to changes in host diet, climate, or pathogen exposure. Integrating hostmicrobiota interactions in human adaptation could offer new approaches to improve our understanding of human health and evolution.

Read more:
The role of the microbiota in human genetic adaptation - Science

Biochemistry

Aid to Navajo Nation is aim of talented biochemistry graduate – ASU Now

November 30, 2020

Editor's note:This story is part of a series of profiles ofnotable fall 2020 graduates.

Fall 2020 graduate Cindy Bonilla-Cirocco says her peers should always keep an open mind about their studies and career path. Fall 2020 graduate Cindy Bonilla-Cirocco will be receiving her PhD in Latin American literature and culture in December. Earlier this year, she successfully defended her dissertation on the Caliwood movement of the 1970s in Colombian cinema. Download Full Image

I would encourage students not to limit themselves and to do their research about what other options are out there, said Bonilla-Cirocco, who will be receiving her PhD in Latin American literature and culture. You never know when you may find a great opportunity you werent expecting if you keep yourself open to it!

Luckily, Bonilla-Cirocco took her own advice.

Midway through the process of researching and writing her dissertation, she enrolled in a Latin American film course taught by Spanish Professor Cynthia Tompkins that changed the course of her doctoral studies. After writing a paper about the 2015 documentary film "Todo comenz por el fin (It All Started at the End)" by Colombian director Luis Ospina, Bonilla-Cirocco switched her dissertation topic from Latin American graphic novels to Colombian cinema.

I was immediately drawn to his work and wanted to know more, she said. It was a drastic change, and I had to essentially learn all about Latin American cinema, as well as Colombian cinema, on the fly as I wrote my dissertation.

With Tompkins assistance, Bonilla-Cirocco published her paper about It All Started at the End in the academic journalConfluencia from the University of Northern Colorado. She then developed it into her dissertation by including additional research and analysis on Ospina and other members of the young and subversive Caliwood filmmaking collective that he was a part of in the 1970s, including Carlos Mayolo.

Bonilla-Cirocco succeeds in highlighting the political commitment of these filmmakers, who risked international success by rejecting and lampooning the Colombian pornomiseria movies of the time that profited from showing the most sordid aspects of the third world, both in terms of the production of a movie as well as penning a manifesto of their own, said Tompkins, who also served as Bonilla-Cirocco's dissertation committee chair.

Bonilla-Cirocco said she was determined to convey her newly discovered passion for Colombian cinema in her dissertation, which she successfully defended in October.

This was a challenging task, and at times I felt overwhelmed, but I knew what my end goal was and I refused to let so many years of hard work and intellectual growth go to waste, Bonilla-Cirocco said. Finishing my dissertation is one of the proudest moments of my life.

During her time at ASU, Bonilla-Cirocco volunteered at various events, such as the School of International Letters and Cultures Language Fair and Homecoming, where she represented SILCs Spanish Department. She also was a member of the organizing committee for ASUs Hispanic Heritage Month celebration, which involved connecting with Spanish-speaking communities around the Valley to showcase various cultures. Bonilla-Cirocco, who was raised in Colombia, served as a liaison to the local Colombian community in particular.

Cindy has an incredible work ethic. She is unassuming, diligent, always well prepared and very professional, said Associate Professor of Spanish Jess Rosales. I believe that Cindy is a socially concerned scholar who is committed to sharing her knowledge, not only with fellow academics, but also with underprivileged communities unable to receive a university education.

Bonilla-Cirocco chose to complete her doctoral studies at ASU after first earning her bachelors degree due to the distinguished reputation of the Spanish program. Doing so allowed her to accept a position as a teaching assistant for Spanish courses at all levels, as well as working as a research assistant for Regents Professor of Spanish David William Foster.

Foster was the original chair of Bonilla-Cirocco's dissertation committee before he diedearlier this year, and he had served as a mentor to her for many years.

There was no better example of a person who was deeply committed to and passionate about his work and his students, Bonilla-Cirocco said. I am honored to have known and worked under him, and I learned things from him that I will remember for the rest of my life."

Bonilla-Cirocco is grateful that Tompkins, who was a member of her dissertation committee at the time, was able to step up into the role of chair and guide her to completing her dissertation and graduating this fall.

While the dissertation is a tribute to the Caliwood movement in general, Bonilla-Cirocco's work is essential in filling a gap in Colombian national cinema, Tompkins said. Im happy to report that Cindy managed to convey her project to Ospina, one of the directors she wrote about, prior to his death in 2019.

After graduating in December, Bonilla-Cirocco hopes to pursue a job in the Foreign Service with the U.S. Department of State. Shes also considering work in academia.

When I entered (the School of International Letters and Cultures) as a graduate student, a professor told me that these would be the best years of my life. I can say now, without a shadow of doubt, that these years here at (ASU) have been the most memorable so far, Bonilla-Cirocco said. During my time at (the school), I grew as an individual, as an intellectual and as an educator.

Follow this link:
Aid to Navajo Nation is aim of talented biochemistry graduate - ASU Now